Emerging Products Provide Opportunity in Prenatal Diagnostics
By LabMedica International staff writers Posted on 01 Feb 2015 |
The recent increase in opportunity has been revealed in the latest study of women’s health diagnostics by Kalorama Information’s (New York, NY, USA), which has reported extensively on prenatal testing markets for over a decade.
According to the Kalorama report, “Women’s Health Diagnostics Market,” prenatal cytogenetic testing represents an important source of clinical market growth for technologies such as sequencing, microarrays, biomarker immunoassays, and mass spectrometry—technologies found with traditional karyotyping and in situ hybridization in a multibillion prenatal cytogenetics testing market.
“Family planning and coordination of care for a child born with health conditions are increasingly relevant issues,” said Emil Salazar, analyst for Kalorama Information, “While ethical considerations will arise with further market development, prenatal, postnatal, and maternal testing are viable promising cytogenetic screening methods that have seen ready acceptance from many insurers in at-risk populations where the prevalence of genetic disorders (especially chromosomal) justify coverage.”
The report also describes successes of several competitors in the field, including PerkinElmer, Verinata (owned by Illumina), Sequenom, Ariosa Diagnostics, CombiMatrix, Agilent, Affymetrix, among others.
“Companies offering sequencing- and array-based noninvasive prenatal testing (NIPT) services estimate the current addressable market at over USD 1 billion,” said Salazar, “Remaining market development will include insurers’ assessment of the risk threshold for expectant mothers that will permit reimbursement for various NIPT services.” Those services include basic screening, wider genomic screening, reflex testing, and confirmation. Some tests, such as Ariosa Diagnostics’ Harmony test, will also permit further investigation into the efficacy and economy of platforms such as sequencing and microarrays.
Ultimately, prenatal testing represents a very probable continued growth opportunity for the multiple technologies of sequencing, microarrays, and mass spectrometry still emerging in various diagnostic applications.
Kalorama’s report contains additional information about opportunities in the prenatal and other women’s health related testing sectors.
Related Links:
Kalorama Information
Women’s Health Diagnostics Markets, report
According to the Kalorama report, “Women’s Health Diagnostics Market,” prenatal cytogenetic testing represents an important source of clinical market growth for technologies such as sequencing, microarrays, biomarker immunoassays, and mass spectrometry—technologies found with traditional karyotyping and in situ hybridization in a multibillion prenatal cytogenetics testing market.
“Family planning and coordination of care for a child born with health conditions are increasingly relevant issues,” said Emil Salazar, analyst for Kalorama Information, “While ethical considerations will arise with further market development, prenatal, postnatal, and maternal testing are viable promising cytogenetic screening methods that have seen ready acceptance from many insurers in at-risk populations where the prevalence of genetic disorders (especially chromosomal) justify coverage.”
The report also describes successes of several competitors in the field, including PerkinElmer, Verinata (owned by Illumina), Sequenom, Ariosa Diagnostics, CombiMatrix, Agilent, Affymetrix, among others.
“Companies offering sequencing- and array-based noninvasive prenatal testing (NIPT) services estimate the current addressable market at over USD 1 billion,” said Salazar, “Remaining market development will include insurers’ assessment of the risk threshold for expectant mothers that will permit reimbursement for various NIPT services.” Those services include basic screening, wider genomic screening, reflex testing, and confirmation. Some tests, such as Ariosa Diagnostics’ Harmony test, will also permit further investigation into the efficacy and economy of platforms such as sequencing and microarrays.
Ultimately, prenatal testing represents a very probable continued growth opportunity for the multiple technologies of sequencing, microarrays, and mass spectrometry still emerging in various diagnostic applications.
Kalorama’s report contains additional information about opportunities in the prenatal and other women’s health related testing sectors.
Related Links:
Kalorama Information
Women’s Health Diagnostics Markets, report
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance